JELLYFISH
23.2.2021 15:02:15 CET | Business Wire | Press release
Jellyfish , the digital marketing partner to the world's leading brands (i.e., Samsung, Uber, Nestle, Deckers, Spotify, and eBay), announced today the acquisition of 5 companies—each a known leader in the digital space. Jellyfish’s rapid expansion comes against a backdrop of consolidation and challenges in the traditional agency sector as the company’s capabilities lie in helping brands during their digital transformation journey. Jellyfish’s expansion follows previous acquisitions with a significant investment from Fimalac Group in 2019. The company represents a new kind of digital business, where agency services are combined with consultancy, training, and cutting-edge technologies to deliver the best possible outcomes for clients. Launched in 2005, it has also become one of a select few globally managed Google Marketing Platform Partners, growing at an average of 45% per annum consistently over the last eight years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005716/en/
Current eMarketer forecasts indicate that total media ad spend is expected to hit more than 600 billion in 2021 thus, to remain competitive, and to increase media effectiveness, companies must cut through a saturated digital landscape and provide seamless, relevant communications across all channels and touchpoints. The acceleration of digital transformation in response to the global pandemic has created a greater need for brands to partner with companies that can help them navigate and meet the challenges of driving growth and sustainability.
“Our mission is to ensure that our clients have all the resources needed to fully embrace digital transformation and reach results that transcend every expectation. Coming off a year of unprecedented disruption and transformation in digital marketing, Jellyfish continues to grow worldwide, entering new markets of Australia and Mexico and increasing our presence in France, Brazil, and the US—adding new capability and talent around the globe, with a focus on content creation and localization, e-commerce, creative, and data optimization,” says Rob Pierre CEO of Jellyfish. “These acquisitions are key in driving prominence and growth in the marketplace and we believe nothing is impossible or beyond the reach of our clients,” Pierre adds.
“These acquisitions bring powerful enhancements to our portfolio of services by expanding our depth of expertise, geographical reach, and our offerings across several continents and regions,” says Chris Lee, COO, Jellyfish.
Expanded expertise, technologies:
Seelk
Software and consultancy for Amazon Marketplace
Splash
Creative technology and services with global localization
Quill
Global Performance Content for e-commerce
Webedia Brand Services
Gamification, content, data, technology services and enterprise data strategies
Expanded global footprint:
Data Runs Deep - Australia
Consulting, implementation, and training for data solutions
For additional information on each Jellyfish acquisition company, click here .
Other recent acquisitions that expanded our global footprint:
Reamp - Brazil
Programmatic marketing, marketing automation, and digital campaign performance (acquired in H2 2020)
San Pancho - Mexico & Colombia
Full-funnel digital marketing capabilities and analytics expertise (acquired in H2 2020)
About Jellyfish
Jellyfish, part of the Fimalac Group, is a global partner in digital marketing and transformation to some of the world's leading brands including Samsung, Uber, Nestle, Orange, Spotify & eBay. Jellyfish represents a new kind of digital business, where agency services are combined with consultancy, training, and cutting-edge technologies to deliver the best possible outcomes for clients. Employing over 2000 people across 40 offices globally, and with further expansion on the horizon, Jellyfish aims to be the first-choice global partner for any brand’s digital requirements. Launched in 2005, Jellyfish has also grown to become one of a select few globally managed Google Marketing Partners. Growing at an average of 45% per annum consistently over the last eight years, Jellyfish is proud to be at the forefront of the global digital economy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005716/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
